

Giant Cell Arteritis

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03923738 2018-004718-17
WP41152

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the pharmacokinetics, pharmacodynamics, and safety of two dose levels of tocilizumab (TCZ) administered by intravenous (IV) infusion every 4 weeks (Q4W) to participants with giant cell arteritis (GCA).

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT03923738 2018-004718-17 WP41152
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥50 Years

Healthy Volunteers
No